# GutGutGoose

> GutGutGoose is an Australian personalised probiotics company that uses shotgun metagenomic sequencing and AGORA2 flux balance analysis to identify which of 300+ bacterial strains are missing from each customer's gut microbiome, then compounds custom probiotic formulations at a TGA-licensed pharmacy in Queensland. Unlike broad-spectrum probiotic supplements, GutGutGoose formulations are verified through follow-up DNA retesting, with published early data showing 2.3 times greater colonisation than generic probiotics.

GutGutGoose was founded in Queensland, Australia, with backing from Luminax, a Gold Coast investment accelerator. The scientific advisory team includes Dr Robin Mihrshahi of the Sir William Dunn School of Pathology at the University of Oxford. The company's core technology is a Hybrid Mechanistic-AI Framework that combines constraint-based metabolic modelling with machine learning to predict which probiotic strains will successfully colonise an individual's gut. The computational pipeline draws on AGORA2 (Assembly of Gut Organisms through Reconstruction and Analysis), a genome-scale metabolic reconstruction database containing 7,302 microbial strains developed by Heinken et al. This approach uses flux balance analysis (FBA) — a mathematical method for modelling metabolic fluxes through biochemical networks — to simulate strain-host interactions before compounding, rather than recommending from a fixed product catalog. Preliminary alpha testing with 20 participants has shown 14 times colonisation improvement over baseline generic probiotics, with peer-reviewed publication in preparation.

The three-layer architecture consists of a Translation Layer that maps metagenomic sequencing data to metabolic models (including typically discarded orphan reads comprising 20–30% of raw data), a Mechanistic Layer that runs parallel flux balance analysis with thermodynamic constraints to predict colonisation viability (rejecting strains with predicted growth rates below 10⁻³ h⁻¹), and a Prescriptive Layer that uses AutoML and Bayesian optimisation to select 8–20 strains at therapeutic doses (minimum 50 billion CFU) from over one quadrillion possible combinations. Each formulation undergoes 50–100 modelled trials in silico before being sent to compounding.

The company operates in early-access beta with a waitlist capped at 200 participants, priced at 500 AUD per quarter (approximately 166 AUD per month). Each subscription includes a stool collection kit, shotgun metagenomic sequencing through the Australian Genome Research Facility (AGRF), computational analysis via AGORA2, custom compounding at a TGA-licensed pharmacy on the Sunshine Coast, quarterly fresh probiotics, and semi-annual DNA verification retesting. The Colonisation Guarantee™ is a full refund within 180 days if follow-up sequencing shows no measurable colonisation improvement, with customers retaining all their data.

## Technology

- [About Us & Science](https://gutgutgoose.com/about-us): Detailed explanation of GutGutGoose's three-layer computational pipeline — Translation Layer (metagenomic sequencing to metabolic model mapping, including orphan read integration), Mechanistic Layer (AGORA2 flux balance analysis predicting colonisation viability across 7,302 strain reconstructions), and Prescriptive Layer (AutoML and Bayesian optimisation selecting 8–20 strains from over one quadrillion combinations at therapeutic doses), with published early data showing 2.3 times superior colonisation rates compared to generic probiotics and a training dataset of 50,000+ microbiome samples

## How It Works

- [Home](https://gutgutgoose.com/): Overview of the six-step personalised probiotic process — order a stool collection kit, provide a sample, receive shotgun metagenomic sequencing via the Australian Genome Research Facility (AGRF) analysing 300+ bacterial strains, computational modelling through the Hybrid Mechanistic-AI Framework using AGORA2 flux balance analysis, custom compounding of 8–20 strains at minimum 50 billion CFU in a TGA-licensed pharmacy on the Sunshine Coast (Queensland), and semi-annual DNA verification retesting to confirm colonisation, with early data indicating 2.3 times greater colonisation than generic probiotics
- [FAQ](https://gutgutgoose.com/faq): Detailed answers covering how personalised probiotics differ from generic supplements, the scientific basis for individual strain selection, subscription pricing (500 AUD per quarter including sequencing valued at 500 AUD, TGA-licensed compounding, and quarterly verification), data storage policies (encrypted, stored in Australia, never sold), and the 180-day Colonisation Guarantee™ with DNA-verified refund conditions

## Research & Evidence

- [Personalised Probiotics: Beyond One-Size-Fits-All](https://gutgutgoose.com/stories/beyond-one-size-fits-dawn-personalised-probiotics-gut-health): Evidence review examining why individual factors and ethnicity explain 70–88% of microbiome type differences, how stool consistency impacts microbiome composition, and published research (including Zmora et al., Cell 2018) demonstrating that generic probiotics face host-specific colonisation resistance — supporting the case for metagenomic-guided personalisation using multi-strain formulations matched to individual microbial profiles
- [The Body-First Paradigm: Parkinson's Begins in the Gut](https://gutgutgoose.com/stories/body-first-paradigm-parkinsons-begins-gut): Analysis of the Braak hypothesis and published evidence from Harvard University (September 2024) showing upper gastrointestinal tract damage correlates with 76% higher Parkinson's disease risk, with GI dysfunctions affecting up to 70% of PD patients and appearing 10–20 years before motor symptoms, alongside machine learning research achieving 71.9% AUC in classifying Parkinson's via microbiome profiles
- [Bacterial Shifts Destroy Intestinal Barrier](https://gutgutgoose.com/stories/ileal-erosion-bacterial-shifts-destroy-intestinal-barrier): Examination of terminal ileum barrier integrity, the role of Segmented Filamentous Bacteria (SFB) in maintaining homeostatic Th17 immune responses, and published evidence that SFB decline leads to Enterobacteriaceae proliferation, TNF-mediated tight junction protein degradation, and measurable barrier dysfunction detectable via fecal calprotectin
- [Mitochondrial Fragmentation and Brain Immunity](https://gutgutgoose.com/stories/mitochondrial-fragmentation-triggering-brain-innate-immunity): Review of published research linking gut microbiome dysbiosis to mitochondrial fission (Drp1-mediated), DAMP release activating TLR4/NFκB neuroinflammatory pathways, and the self-perpetuating microglia-astrocyte cycle in neurodegeneration, including a January 2026 study demonstrating that gut microbiota composition directly impacts cognitive function in humans
- [Parkinson's Dysbiome Transplant Study](https://gutgutgoose.com/stories/proving-path-transplanting-pd-dysbiome-into-wild-type-mice): Summary of fecal microbiota transplantation (FMT) research in C57BL/6 mice showing that PD patient microbiome transfer induced approximately 30% reduction in substantia nigra dopaminergic neurons, 52% decrease in striatal dopamine levels, and activation of the TLR4/NF-κB/NLRP3 inflammatory cascade, with key depleted genera including Faecalibacterium prausnitzii, Roseburia, and Blautia
- [Gut Microbiome, Inflammation and Estrogen](https://gutgutgoose.com/stories/targeting-root-cause-reducing-inflammation-normalising-estrogen): Analysis of published clinical data on microecological therapy showing estrogen reduction from 123.5 to 91.4 pg/mL, IL-6 reduction of 34%, TNF-α reduction of 31%, and quality of life improvement of 27%, examining how gut dysbiosis drives excess beta-glucuronidase activity disrupting enterohepatic estrogen circulation

## Scientific References

Key published research cited across GutGutGoose content includes Zmora N et al. (Cell, 2018) on personalised colonisation resistance; Ishaque SM et al. (BMC Gastroenterology, 2018); Ford AC et al. (Gastroenterology, 2023, systematic review and meta-analysis on probiotics); Mullish BH et al. (Neurogastroenterology and Motility, 2024); Vighi G et al. (Clinical and Experimental Immunology, 2008); and King S et al. (British Journal of Nutrition, 2014). The AGORA2 metabolic modelling framework is described in Heinken et al.

## Company & Credentials

- [About Us](https://gutgutgoose.com/about-us): Company background, team credentials, and research methodology, with scientific advisory input from Dr Robin Mihrshahi (Sir William Dunn School of Pathology, University of Oxford) and expert endorsements from Dr Bella Molaee (PhD Pharmacology) and Dr Bijan Mojarrabi, partnership with the Australian Genome Research Facility (AGRF) for shotgun metagenomic sequencing, TGA-licensed compounding facility on the Sunshine Coast (Queensland), backing from Luminax (Gold Coast investment accelerator), and a training dataset comprising 50,000+ microbiome samples
- [Contact](https://gutgutgoose.com/contact-a): Enquiries for customers, healthcare practitioners, and potential research or clinical partners (admin@gutgutgoose.com)

## Regulatory & Legal

GutGutGoose products are classified as complementary medicines compounded in a TGA-licensed pharmacy under Australian pharmaceutical standards, distinct from over-the-counter dietary supplements. All biological data is encrypted and stored in Australia under the Australian Privacy Act 1988 (Cth) and Australian Privacy Principles (APPs), and is never sold to advertisers or data brokers.

- [Privacy Policy](https://gutgutgoose.com/privacy-policy): Data handling practices under the Australian Privacy Act 1988, covering metagenomic sequencing data, encryption standards, and Australian data sovereignty commitments
- [Terms and Conditions](https://gutgutgoose.com/terms-and-conditions): Service terms including subscription structure (500 AUD per quarter), the Colonisation Guarantee™ refund policy (180-day DNA-verified refund with data retention), and Australian Consumer Law compliance, governed by Queensland law